Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2015 01:00 ET | Source: Celyad

Celyad Treats First Patient of Second Cohort in NKG2D CAR T-Cell Phase I Trial

MONT-SAINT-GUIBERT, Belgium, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
November 19, 2015 01:00 ET | Source: Celyad

Celyad Announces Third Quarter 2015 Business Update

MONT-SAINT-GUIBERT, Belgium, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
November 10, 2015 01:00 ET | Source: Celyad

Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial

No treatment-related safety issues reported at 30 days post-treatment of all patients in first cohort of the trial following single dose NKG2D CAR T-Cell infusion Triggers enrolment of first...
November 06, 2015 01:00 ET | Source: Celyad

Celyad CEO Invited to Present at 2015 CAR-T Summit in Massachusetts

MONT-SAINT-GUIBERT, Belgium, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
October 23, 2015 01:00 ET | Source: Celyad

First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified to Reduce Immunogenicity is Awarded to Celyad

MONT-SAINT-GUIBERT, Belgium, Oct. 23, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with...
September 15, 2015 01:00 ET | Source: Celyad

Celyad Announces the Appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology

MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
September 04, 2015 01:00 ET | Source: Celyad

Celyad Announces the Appointment of Dr. Debasish Roychowdhury as Independent Director

MONT-SAINT-GUIBERT, Belgium, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today...
August 31, 2015 01:00 ET | Source: Celyad

Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China

All costs leading to market approval to be paid by local partner New agreement contains high double digit royalties and profit sharing MONT-SAINT-GUIBERT, Belgium, Aug. 31, 2015 (GLOBE NEWSWIRE)...
August 25, 2015 01:00 ET | Source: Celyad

Celyad Reports First Half 2015 Financial Results and Operational Progress

MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development...
August 12, 2015 01:30 ET | Source: Celyad

Celyad Announces Details of Upcoming Half Year 2015 Financial Results

MONT-SAINT-GUIBERT, Belgium, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development...